integration of arv toxicity surveillance into hiv ... · arv toxicity surveillance into hiv...

22
Excellent healthcare – locally delivered Integration of ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity surveillance: sharing preliminary results and lessons learnt, identifying solutions 7 - 8 November 2013, Geneva

Upload: others

Post on 12-Oct-2020

9 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Excellent healthcare – locally delivered

Integration of

ARV toxicity surveillance into

HIV monitoring and evaluation

Technical review meeting of country experiences in ARV toxicity surveillance: sharing preliminary results and lessons

learnt, identifying solutions 7 - 8 November 2013, Geneva

Page 2: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Outline

1. Consolidated strategic information guide for HIV in the health sector, to be released July 2014 2. Integrating Toxicity Monitoring into M&E Systems

17/01/2014 2

Page 3: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Consolidated HIV Strategic Information Guide

2014 Consolidated HIV SI Guide

Page 4: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Type date

Why consolidation?

WHO, 2005 ART M&E guide

WHO, 2009 TB/HIV M&E guide

WHO, 2011

HTC M&E guide

WHO, 2012

PMTCT

Impact Measurement Guide

WHO, 2013 PWID Target setting guide

WHO/UNAIDS, 2013 HIV surveillance bundle

UNAIDS/WHO/ UNICEF, 2012 GARPR core indicators

WHO, 2013 3 ILPMS WHO, 2011

PSM M&E guide

WHO, 2012 Drug resistance Surveillance, M&E

GFATM, 2011 M&E Toolkit

PEPFAR, 2013 MER Guide

WHO/UNAIDS, 2010 Estimating the size of populations most at risk to HIV

WHO, 2010 Health Systems Monitoring

Page 5: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Type date

2014 Consolidated HIV SI Guide

• “All you need to know to manage your health sector HIV programme”

• Organized along the cascade of HIV care, also includes surveillance, M&E, impact, HIVDR, toxicity monitoring, systems strengthening

Consolidated HIV SI Guide

for the Health Sector

2014

Over 30 existing guides!

Page 6: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

“All you need to know to manage your HIV health sector response” Chapter 1: Introduction Chapter 2: Indicators (and data elements)

i. Methods ii. Utility for programme improvement

Section 3: SI systems Emphasize essential components of generating Health sector HIV data

3ILPMS: Three Interlinked Patient Monitoring System (set of generic tools-patient cards, registers, reporting forms)

will also be updated and linked to the SI guide

Structure and content

Page 7: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Integrating Toxicity Monitoring into M&E Systems

2014 Consolidated HIV SI Guide

Page 8: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Toxicity Monitoring in SI Guide • Recommend Toxicity Monitoring as Key

component of Strategic Information for HIV programme.

• Especially as ART is scaled up and more people start ART earlier and longer on a wide scale, implementation of toxicity monitoring is critical for HIV programmes to monitor safety.

• Need to address how best to implement the toxicity monitoring system in a given country.

17/01/2014 8

Page 9: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Toxicity Monitoring – M&E • How can we implement TM beyond special

studies in sentinel sites

• Can we integrate selected components of TM within routine monitoring systems?

• Integrating it into routine M&E systems means potentially more data (more or all sites) but may also lead to more variability in quality of data and interpretation of reported data.

17/01/2014 9

Page 10: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Generic Tools

1. HIV Patient Card – one card/file per individual 2. ART Register – summary of key variable to facilitate data aggregation and reporting

3. Reporting Forms

1. Cohort Reporting From 2. Cross-sectional Reporting From 3. Toxicity Monitoring form??

17/01/2014 10

Page 11: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

17/01/2014 11

HIV Care Card - 1

Sociodemographic Variables

Prior ARVs ARV start date ARV regimen

Treatment Substitution or Interruption and WHY, including toxicity/side effects as a possible reason

Page 12: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

17/01/2014 12

Potential side effects

OIs or other problems

Reasons for poor adherence, including toxicity

HIV Care Card - 2

Page 13: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

17/01/2014 13

ART Register – 1: for selected data to aggregate and report

No specific adverse event

Page 14: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

17/01/2014 14

ART Register - 2

Page 15: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Generic Tools

1. HIV Patient Card – one card/file per individual 2. ART Register – summary of key variable to facilitate data aggregation and reporting

3. Reporting Forms

1. Cohort Reporting From 2. Cross-sectional Reporting From 3. Toxicity Monitoring form??

17/01/2014 15

Page 16: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Reporting Forms

17/01/2014 16

ART Cohort Reporting Form: Report on a group of patients’ status at time x after initation

Out of all patients who started ART in a given month , what was there status 12 m later: - On ART (1st line, 2nd line) - Stopped - Died - Lost No reason, no link to molecule

On 1st Line Regimen

Page 17: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

17/01/2014 17

Cross sectional reporting form

On 1st Line Regimen

On 2nd Line Regimen

What to report up for toxicity monitoring? Specific TM reporting form

Page 18: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Using routine data

• Routine reporting from facilities – Paper-based system: simple and small set of data

reported up monthly or quarterly – Electronic system: core set of data for toxicity

monitoring categorized for routine reporting

• Retrospective data extraction, based on: – Various inclusion/exclusion criteria – Various disaggregation or target population of

interest 18

Page 19: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Integration with M&E Pros

• More data from larger number of facilities and patients.

• Potentially more representative characterization of toxicities

• Potentially saves cost with less resource-intensive approach compared to research/special studies

Cons

• Reporting on adverse events (and serious adverse events) may be more under-reported.

• Training and supervision may not be as rigorous as research/pilot/sentinel sites.

• Diagnostic capacity • Less detailed information

available. • No incentive(?) but more

work load • Data interpretation?

17/01/2014 19

Page 20: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Issues to Consider • What adverse reactions are worth collecting

routinely everywhere? • Minimum set of data elements - adverse events

to be recorded in patient cards and reported up • Criteria/conditions to make this work

17/01/2014 20

Is it worth it? TM Data Collected through routine monitoring system (benefit)

≥ Effort and Resources required to report extra TM related data (cost)

Page 21: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Indicators for TM Possible indicators:

• % of treatment discontinuation or substitution due to ARV toxicity

• % of life-threatening illness* and death due to ARV toxicity

* Life-threatening illness defined as a serious drug reaction , together with death, hospitalization, disability, and congenital anomalies.

Currently, WHO generic routine registers collect treatment discontinuation and deaths by ART start cohort. Can consider including in the cross-sectional form or a TM-specific reporting form (which can also include other drugs).

21

Page 22: Integration of ARV toxicity surveillance into HIV ... · ARV toxicity surveillance into HIV monitoring and evaluation Technical review meeting of country experiences in ARV toxicity

Thank you

17/01/2014 22